中文名稱:Capecitabine | 英文名稱:Capecitabine |
CAS:154361-50-9 | 品牌: 一研 |
保存條件: Store at -20°C | 產(chǎn)品類別: 抑制劑 |
Cas : 154361-50-9 |
產(chǎn)品屬性:
產(chǎn)品名稱 | 規(guī)格 | CAS號(hào) | 型號(hào) |
Capecitabine | 10mM (in 1mL DMSO) 50mg | 154361-50-9 | EY-Y0165406 |
Cas No.154361-50-9
別名
化學(xué)名 pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
分子式 C15H22FN3O6
分子量 359.35
溶解度 ≥ 17.95mg/mL in DMSO
儲(chǔ)存條件 Store at-20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述:
In vitro: In antiproliferative assays, both LS174T WT and LS174T-c2 cells were more sensitive to capecitabine when cultivated in the same plates as HepG2 hepatoma. In LS174T WT alone and cultivated with HepG2, IC50values of capecitabine were 890 ± 48 and 630 ± 14 μm respectively. The IC50fell from 330 ± 4 down to 89 ± 6 μmin LS174T-C2 subline when cultivated in the same plates as hepatoma cells.In the LS174T-c2 subclone, whereas little cell death occurred in cells exposed to capecitabine, both early and late apoptosis were increased by 244 and 262%, respectively [1]. Furthermore, Capecitabine induces apoptosis in a Fas-dependent manner, and shows a 7-fold higher cytotoxicity and markedly stronger apoptotic potential in thymidine phosphorylase (TP)-transfected LS174T-c2 cells [2].
In vivo:Capecitabine was effective in a wider dose range in CXF280, HCT116, COLO205, and WiDr human colon cancer xenograft models [2]. In highly metastatic nude mice model, capecitabine inhibited tumor growth and metastatic recurrence after resection of HCC attributed to the high expression of PD-ECGF in tumors [3].
References:
[1]. Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts[J]. Biochemical pharmacology, 1998, 55(7): 1091-1097.
[2]. Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts[J]. Biochemical pharmacology, 1998, 55(7): 1091-1097.
[3]. Zhou J, Tang Z Y, Fan J, et al. Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor[J]. Clinical cancer research, 2003, 9(16): 6030-6037.
成立日期 | 2014-06-05 (12年) | 注冊(cè)資本 | 100 |
員工人數(shù) | 50-100人 | 年?duì)I業(yè)額 | ¥ 100萬以內(nèi) |
主營行業(yè) | 生化試劑,抗體,細(xì)胞培養(yǎng),分子生物學(xué),免疫安全 | 經(jīng)營模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP2年
|
湖北鴻福達(dá)生物科技有限公司
|
2025-06-21 | |
詢價(jià) |
VIP10年
|
滄州恩科醫(yī)藥科技有限公司
|
2025-06-21 | |
詢價(jià) |
VIP1年
|
滄州恩科醫(yī)藥科技有限公司
|
2025-06-21 | |
詢價(jià) |
VIP5年
|
深圳菲斯生物科技有限公司
|
2025-06-20 | |
詢價(jià) |
VIP6年
|
湖北威德利化學(xué)試劑有限公司
|
2025-06-20 | |
詢價(jià) |
VIP2年
|
普善實(shí)業(yè)(陜西)有限公司
|
2025-06-20 | |
詢價(jià) |
VIP6年
|
武漢弘德悅欣醫(yī)藥科技有限公司
|
2025-06-20 | |
詢價(jià) |
VIP12年
|
深圳振強(qiáng)生物技術(shù)有限公司
|
2025-06-20 | |
詢價(jià) |
VIP6年
|
濟(jì)寧心和化工有限公司
|
2025-06-20 | |
詢價(jià) |
VIP6年
|
眾鑫辰實(shí)(武漢)科技有限公司
|
2025-06-20 |